News | December 05, 2011

Obesity Predicts Higher Quality Of Life Following AF Catheter Ablation

December 5, 2011 – New study shows significant increase in quality of life (QoL) among overweight patients following ablation of atrial fibrillation (AF), compared to patients with a lower body mass index (BMI) where no substantial improvement was observed.  The study, published in the December edition of HeartRhythm, the official journal of the Heart Rhythm Society, reveals an association between BMI and a change in QoL between the pre- and postablation periods in a large AF patient cohort.  The study also verifies comparable procedural success rates of ablation in both overweight and lean patients. 

This study, co-led by Sanghamitra Mohanty, M.D., and Andrea Natale, M.D., at St. David’s Medical Center (SDMC) in Austin, Texas, is the first to use four different assessment tools* to measure QoL in AF patients undergoing catheter ablation, and examined the association between BMI and improvement in QoL scores following ablation in 660 patients.  Patients were categorized into two groups: lean or normal with a normal-BMI (BMI < 25) and overweight or obese with a high-BMI (BMI ? 25), 79 percent of patients had a high-BMI.  Patients were asked to participate in self-administered QoL surveys before and 12 months after the catheter ablation procedure.

While high-BMI patients started with a lower baseline QoL score compared to normal-BMI patients, 12-month postablation QoL scores among the high-BMI group improved significantly in all measures except physical functioning and bodily pain.  Specifically, improvement was observed in role limitations due to physical health (27 percent), role limitations due to emotional problem (22.6 percent) and vitality (21.9 percent).  The high-BMI group also reported reductions in anxiety and depression levels after ablation procedures.  Overall, long-term ablation success was the same in both the normal-BMI group (69 percent) and high-BMI group (63 percent).

“Despite reporting improvement in QoL and comparable procedure-success in obese and overweight patients, this study does not attempt to trivialize the importance of interventions to promote weight loss and adaptation of healthy life style,” said co-lead author Mohanty at SDMC, Austin, Texas. “Obesity still remains a potential risk-factor for AF and many other cardio-vascular diseases and active measures should be taken to reverse this potentially modifiable risk factor.”

*Quality of Life Assessment tools used in the study include, Medical Outcomes Study Short Form-36 (SF-36), Beck Depression Inventory (BDI), Hospital Anxiety and Depression (HAD) scale, and State-Trait Anxiety Inventory (STAI).

For more information: www.hrsonline.org/publications/

 


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now